Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2025.0
(0.75%)
JPY 2025.0
(0.75%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 46.89 Billion JPY | 3.98% |
| 2022 | 45.1 Billion JPY | 3.77% |
| 2021 | 43.46 Billion JPY | -10.77% |
| 2020 | 48.7 Billion JPY | 8.25% |
| 2019 | 44.99 Billion JPY | 9.39% |
| 2018 | 41.13 Billion JPY | 3.14% |
| 2017 | 39.88 Billion JPY | 5.03% |
| 2016 | 37.97 Billion JPY | 4.52% |
| 2015 | 36.33 Billion JPY | 6.66% |
| 2014 | 34.06 Billion JPY | 9.17% |
| 2013 | 31.2 Billion JPY | 7.75% |
| 2012 | 28.95 Billion JPY | 6.67% |
| 2011 | 27.14 Billion JPY | 7.66% |
| 2010 | 25.21 Billion JPY | 11.19% |
| 2009 | 22.67 Billion JPY | 5.68% |
| 2008 | 21.46 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.67 Billion JPY | 3.64% |
| 2023 Q3 | 10.55 Billion JPY | -11.57% |
| 2023 Q4 | 12.23 Billion JPY | 15.93% |
| 2023 FY | 46.89 Billion JPY | 3.98% |
| 2023 Q2 | 11.93 Billion JPY | -2.02% |
| 2023 Q1 | 12.17 Billion JPY | 15.64% |
| 2022 Q3 | 11.2 Billion JPY | -1.09% |
| 2022 Q1 | 12.04 Billion JPY | 21.86% |
| 2022 Q2 | 11.32 Billion JPY | -5.94% |
| 2022 FY | 45.1 Billion JPY | 3.77% |
| 2022 Q4 | 10.53 Billion JPY | -6.0% |
| 2021 Q4 | 9.88 Billion JPY | -11.14% |
| 2021 Q1 | 11.74 Billion JPY | 8.06% |
| 2021 Q2 | 10.71 Billion JPY | -8.77% |
| 2021 FY | 43.46 Billion JPY | -10.77% |
| 2021 Q3 | 11.11 Billion JPY | 3.76% |
| 2020 Q2 | 12.33 Billion JPY | -10.0% |
| 2020 Q3 | 11.8 Billion JPY | -4.31% |
| 2020 Q4 | 10.87 Billion JPY | -7.89% |
| 2020 Q1 | 13.7 Billion JPY | 29.01% |
| 2020 FY | 48.7 Billion JPY | 8.25% |
| 2019 Q1 | 11.65 Billion JPY | 8.64% |
| 2019 FY | 44.99 Billion JPY | 9.39% |
| 2019 Q2 | 11.59 Billion JPY | -0.54% |
| 2019 Q3 | 11.11 Billion JPY | -4.11% |
| 2019 Q4 | 10.62 Billion JPY | -4.47% |
| 2018 Q3 | 10.25 Billion JPY | -1.46% |
| 2018 Q2 | 10.4 Billion JPY | 6.87% |
| 2018 Q4 | 10.73 Billion JPY | 4.64% |
| 2018 FY | 41.13 Billion JPY | 3.14% |
| 2018 Q1 | 9.73 Billion JPY | -4.94% |
| 2017 Q3 | 9.18 Billion JPY | -14.77% |
| 2017 Q1 | 9.68 Billion JPY | -3.67% |
| 2017 FY | 39.88 Billion JPY | 5.03% |
| 2017 Q4 | 10.24 Billion JPY | 11.57% |
| 2017 Q2 | 10.77 Billion JPY | 11.27% |
| 2016 Q1 | 9.11 Billion JPY | -2.28% |
| 2016 FY | 37.97 Billion JPY | 4.52% |
| 2016 Q4 | 10.05 Billion JPY | 15.54% |
| 2016 Q3 | 8.69 Billion JPY | -13.95% |
| 2016 Q2 | 10.11 Billion JPY | 10.96% |
| 2015 FY | 36.33 Billion JPY | 6.66% |
| 2015 Q1 | 8.73 Billion JPY | -7.22% |
| 2015 Q4 | 9.32 Billion JPY | 7.3% |
| 2015 Q3 | 8.68 Billion JPY | -9.35% |
| 2015 Q2 | 9.58 Billion JPY | 9.75% |
| 2014 Q4 | 9.41 Billion JPY | 18.26% |
| 2014 Q1 | 7.42 Billion JPY | -18.62% |
| 2014 Q2 | 9.26 Billion JPY | 24.81% |
| 2014 FY | 34.06 Billion JPY | 9.17% |
| 2014 Q3 | 7.96 Billion JPY | -14.08% |
| 2013 Q4 | 9.12 Billion JPY | 35.64% |
| 2013 FY | 31.2 Billion JPY | 7.75% |
| 2013 Q3 | 6.72 Billion JPY | -18.93% |
| 2013 Q1 | 7.05 Billion JPY | -9.48% |
| 2013 Q2 | 8.29 Billion JPY | 17.5% |
| 2012 Q3 | 6.52 Billion JPY | -14.81% |
| 2012 FY | 28.95 Billion JPY | 6.67% |
| 2012 Q2 | 7.66 Billion JPY | 10.04% |
| 2012 Q1 | 6.96 Billion JPY | -5.8% |
| 2012 Q4 | 7.79 Billion JPY | 19.45% |
| 2011 Q1 | 6.39 Billion JPY | -6.38% |
| 2011 FY | 27.14 Billion JPY | 7.66% |
| 2011 Q2 | 7.38 Billion JPY | 15.48% |
| 2011 Q3 | 5.97 Billion JPY | -19.02% |
| 2011 Q4 | 7.39 Billion JPY | 23.66% |
| 2010 Q1 | 5.72 Billion JPY | 0.0% |
| 2010 Q3 | 6.11 Billion JPY | -6.47% |
| 2010 FY | 25.21 Billion JPY | 11.19% |
| 2010 Q4 | 6.82 Billion JPY | 11.61% |
| 2010 Q2 | 6.54 Billion JPY | 14.19% |
| 2009 Q2 | 6.09 Billion JPY | 0.0% |
| 2009 FY | 22.67 Billion JPY | 5.68% |
| 2008 FY | 21.46 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 24.542% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 98.9% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 85.092% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 89.222% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | -506.002% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 68.369% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 34.908% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 93.678% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | -278.003% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 66.907% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 54.42% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 15.361% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | -52.514% |
| Tsumura & Co. | 150.84 Billion JPY | 68.912% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 37.952% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 14.171% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 79.426% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | -14.689% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 38.072% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 60.768% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -830.456% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -738.953% |
| MedRx Co., Ltd | 26 Million JPY | -180265.385% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | -326.716% |
| Solasia Pharma K.K. | 617 Million JPY | -7500.486% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 25.378% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 73.485% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -76636.157% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 96.824% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | -111.867% |